To build proteins, cells rely on a molecule called transfer RNA, or tRNA. tRNAs act like protein-building couriers, where ...

To build proteins, cells rely on a molecule called transfer RNA, or tRNA. tRNAs act like protein-building couriers, where ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

GSK agrees €1.4bn deal to take full control of CureVac's mRNA vaccines for flu and COVID-19, as CureVac slashes staff and pivots to oncology.

The top shareholders of Moderna are Stéphane Bancel, Noubar B. Afeyan, Stephen Hoge, Baillie Gifford & Co., Vanguard Group Inc., and BlackRock Inc.

Messenger RNA (mRNA) vaccines hold promise for creating new and improved immunizations; however, their delivery is challenging in terms of compliance, reactogenicity, cost and scalability.